Many recent studies have demonstrated the utility of the albumin–bilirubin (ALBI) grade, which was first described in 2015 by Johnson et al. [16], for evaluating hepatic function and predicting the prognosis of patients with HCC following liver resection [17–20]. Here, ALB is linked to hepatocellular carcinoma.